Should I buy or sell Acasti Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACST shares. View ACST analyst ratings or view top-rated stocks .

What is Acasti Pharma's stock price target for 2024?

2 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $14.40 to $15.00. On average, they expect the company's stock price to reach $14.70 in the next twelve months. This suggests a possible upside of 617.1% from the stock's current price. View analysts price targets for ACST or view top-rated stocks among Wall Street analysts .

How have ACST shares performed in 2023?

Acasti Pharma's stock was trading at $3.0060 at the beginning of the year. Since then, ACST shares have decreased by 31.8% and is now trading at $2.05. View the best growth stocks for 2023 here .

Are investors shorting Acasti Pharma?

Acasti Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 91,900 shares, a drop of 10.0% from the October 31st total of 102,100 shares. Based on an average daily trading volume, of 49,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are sold short. View Acasti Pharma's Short Interest .

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ACST earnings forecast .

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10.

When did Acasti Pharma's stock split?

Acasti Pharma shares reverse split before market open on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB) , SCYNEXIS (SCYX) , Outlook Therapeutics (OTLK) , Bionano Genomics (BNGO) , Sorrento Therapeutics (SRNE) , ADMA Biologics (ADMA) , Heat Biologics (HTBX) , KushCo (KSHB) , Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS) .

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Acasti Pharma Stock Price, News & Analysis (NASDAQ:ACST)

$2.05

-0.03 (-1.44%)

(As of 11/29/2023 ET)

Compare

Today's Range: $2.00
▼
$2.10
50-Day Range: $1.75
▼
$2.95
52-Week Range: $1.72
▼
$5.05

Volume: 13,162 shs
Average Volume: 28,635 shs
Market Capitalization: $19.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.70

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 617.1% Upside
$14.70 Price Target
Short Interest: Healthy
1.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.43
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$1.25 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

92nd out of 949 stocks

Pharmaceutical Preparations Industry

32nd out of 431 stocks

3.5

Analyst's Opinion

Consensus Rating
Acasti Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.70, Acasti Pharma has a forecasted upside of 617.1% from its current price of $2.05.
Amount of Analyst Coverage
Acasti Pharma has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.53% of the float of Acasti Pharma has been sold short.
Short Interest Ratio / Days to Cover
Acasti Pharma has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acasti Pharma has recently decreased by 9.99%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Acasti Pharma does not currently pay a dividend.
Dividend Growth
Acasti Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACST.

3.6

News and Social Media Coverage

News Sentiment
Acasti Pharma has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Acasti Pharma this week, compared to 0 articles on an average week.
Search Interest
4 people have searched for ACST on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Acasti Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acasti Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,252,067.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.51% of the stock of Acasti Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.00% of the stock of Acasti Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Acasti Pharma are expected to grow in the coming year, from ($1.44) to ($1.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acasti Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acasti Pharma is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acasti Pharma has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACST Stock News Headlines

November 13, 2023 | finance.yahoo.com

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

October 18, 2023 | markets.businessinsider.com

Optimistic Outlook for Acasti Pharma’s GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatment

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

October 4, 2023 | finance.yahoo.com

Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)

September 27, 2023 | seekingalpha.com

Acasti announces $7.5M private placement equity funding

July 12, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Acasti Pharma (ACST), ImmunoPrecise Antibodies (IPA)

July 7, 2023 | markets.businessinsider.com

Acasti Pharma: Reverse Stock Split To Become Effective July 10

July 7, 2023 | finance.yahoo.com

Acasti Pharma Announces 1-for-6 Reverse Stock Split

November 30, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

July 5, 2023 | finance.yahoo.com

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

June 23, 2023 | msn.com

Recap: Acasti Pharma Q4 Earnings

May 10, 2023 | finance.yahoo.com

We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely

May 8, 2023 | finance.yahoo.com

Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

April 4, 2023 | finance.yahoo.com

Acasti Announces Appointment of Prashant Kohli as CEO

April 4, 2023 | finance.yahoo.com

Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND

March 30, 2023 | finance.yahoo.com

When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit?

March 30, 2023 | finance.yahoo.com

Acasti Pharma Inc. Announces the Resignation of a Director

March 13, 2023 | finance.yahoo.com

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

February 13, 2023 | msn.com

Acasti Pharma's Earnings Outlook

February 7, 2023 | finance.yahoo.com

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

January 25, 2023 | finance.yahoo.com

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

January 17, 2023 | finance.yahoo.com

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

January 5, 2023 | finance.yahoo.com

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

December 29, 2022 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)

December 29, 2022 | finance.yahoo.com

Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript

December 28, 2022 | finance.yahoo.com

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia

December 22, 2022 | finance.yahoo.com

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

See More Headlines

Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 11/29/2023
Next Earnings (Estimated): 2/13/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACST
CUSIP: N/A
CIK: 1444192
Web: www.acastipharma.com
Phone: 45-0686-4555
Fax: 45-0687-2272
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.70
High Stock Price Target: $15.00
Low Stock Price Target: $14.40
Potential Upside/Downside: +617.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.4091)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,430,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -13.77%
Return on Assets: -11.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.68
Quick Ratio: 20.68

Sales & Book Value

Annual Sales: $200,000.00
Price / Sales: 96.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.10 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 9,400,000
Free Float: 8,129,000
Market Cap: $19.27 million
Optionable: Not Optionable
Beta: 1.34

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Prashant Kohli (Age 51)
CEO & Director
Comp: $358.41k
Mr. Brian D. Ford CPA (Age 64)
CA, Interim Chief Financial Officer
Comp: $379.35k
Dr. R. Loch MacDonald M.D. (Age 61)
Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
Mr. Amresh Kumar Ph.D. (Age 43)
VP of Program Management
Ms. Carrie D'Andrea (Age 51)
VP of Clinical Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings or view top-rated stocks.
What is Acasti Pharma's stock price target for 2024?: 2 brokerages have issued twelve-month target prices for Acasti Pharma's stock. Their ACST share price targets range from $14.40 to $15.00. On average, they expect the company's stock price to reach $14.70 in the next twelve months. This suggests a possible upside of 617.1% from the stock's current price.
View analysts price targets for ACST or view top-rated stocks among Wall Street analysts.
How have ACST shares performed in 2023?: Acasti Pharma's stock was trading at $3.0060 at the beginning of the year. Since then, ACST shares have decreased by 31.8% and is now trading at $2.05.
View the best growth stocks for 2023 here.
Are investors shorting Acasti Pharma?: Acasti Pharma saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 91,900 shares, a drop of 10.0% from the October 31st total of 102,100 shares. Based on an average daily trading volume, of 49,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are sold short.
View Acasti Pharma's Short Interest.
When is Acasti Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ACST earnings forecast.

How were Acasti Pharma's earnings last quarter?: Acasti Pharma Inc. (NASDAQ:ACST) released its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.10.
When did Acasti Pharma's stock split?: Acasti Pharma shares reverse split before market open on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.
What other stocks do shareholders of Acasti Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).
How do I buy shares of Acasti Pharma?: Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial